Annovis Stock Financials

ANVS -  USA Stock  

USD 13.04  0.49  3.62%

Understanding current and past Annovis Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Annovis Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Annovis Bio's assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Annovis Bio's financials over time to get the whole picture.
Annovis Bio Tangible Asset Value is relatively stable at the moment as compared to the past year. Annovis Bio reported last year Tangible Asset Value of 9.34 Million. As of 01/23/2022, Working Capital is likely to grow to about 9.4 M, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (5 M).
You can use fundamental analysis to find out if Annovis Bio is mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to interpolate and analyze data for thirty-two available fundamental indicators for Annovis Bio, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Annovis Bio financials, including its debt to equity, and the relationship between the revenue and number of employees . Given that Annovis Bio has a price to earning of (0.43) X, we suggest you to validate Annovis Bio prevailing market performance to make sure the company can sustain itself down the road. Use Annovis Bio to protect your portfolios against small market fluctuations. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Annovis Bio to be traded at $12.52 in 90 days.

Annovis Fundamentals 

 
Refresh
With this module, you can analyze Annovis financials for your investing period. You should be able to track the changes in Annovis Bio individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
The fundamental analysis of Annovis Bio is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Annovis Bio includes many different criteria found on its balance sheet. For example, investors should never minimize Annovis Bio's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Annovis Bio's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Annovis Bio.

Annovis Bio Cash

Chance Of Financial Distress
Over 94
Annovis Bio has more than 94 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Annovis Bio stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Annovis Bio's official financial statements usually reflect Annovis Bio's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Annovis Bio. For example, before you start analyzing numbers published by Annovis accountants, it's critical to develop an understanding of what Annovis Bio's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Annovis Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Annovis Bio's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Annovis Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Annovis Bio. Please utilize our Beneish M Score to check the likelihood of Annovis Bio's management to manipulate its earnings.

Annovis Bio Company Summary

Annovis Bio competes with Brickell Biotech. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. Annovis Bio operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 2 people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNYSEMKT Exchange
CUSIP03615A108
LocationPennsylvania; U.S.A
Business Address1055 Westlakes Drive
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.annovisbio.com
Phone610 727 3913
CurrencyUSD - US Dollar
You should never invest in Annovis Bio without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Annovis Stock, because this is throwing your money away. Analyzing the key information contained in Annovis Bio's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Annovis Bio Key Financial Ratios

Generally speaking, Annovis Bio's financial ratios allow both analysts and investors to convert raw data from Annovis Bio's financial statements into concise, actionable information that can be used to evaluate the performance of Annovis Bio over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Annovis Bio reports annually and quarterly.

Annovis Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Annovis Bio's current stock value. Our valuation model uses many indicators to compare Annovis Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Annovis Bio competition to find correlations between indicators driving Annovis Bio's intrinsic value. More Info.
Annovis Bio is number one stock in cash per share category among related companies. It is number one stock in beta category among related companies totaling about  0.98  of Beta per Cash per Share. The ratio of Cash per Share to Beta for Annovis Bio is roughly  1.02 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Annovis Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Annovis Bio's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Annovis Bio's earnings, one of the primary drivers of an investment's value.

Annovis Bio Systematic Risk

Annovis Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Annovis Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Annovis Bio correlated with the market. If Beta is less than 0 Annovis Bio generally moves in the opposite direction as compared to the market. If Annovis Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Annovis Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Annovis Bio is generally in the same direction as the market. If Beta > 1 Annovis Bio moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Annovis Bio Financials

What exactly are Annovis Bio Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Annovis Bio's income statement, its balance sheet, and the statement of cash flows. Potential Annovis Bio investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Annovis Bio investors may use each financial statement separately, they are all related. The changes in Annovis Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Annovis Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2019 2020 2021 2022 (projected)
Current Assets747.51 K8.12 M9.34 M10.07 M
Total Assets1.12 M8.12 M9.34 M10.07 M
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Annovis Bio is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Annovis grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Annovis Bio January 23, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Annovis Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Annovis Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Annovis Bio based on widely used predictive technical indicators. In general, we focus on analyzing Annovis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Annovis Bio's daily price indicators and compare them against related drivers.
Information Ratio(0.17)
Maximum Drawdown32.94
Value At Risk(8.23)
Potential Upside11.13
Please continue to Trending Equities. Note that the Annovis Bio information on this page should be used as a complementary analysis to other Annovis Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Annovis Stock analysis

When running Annovis Bio price analysis, check to measure Annovis Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annovis Bio is operating at the current time. Most of Annovis Bio's value examination focuses on studying past and present price action to predict the probability of Annovis Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Annovis Bio's price. Additionally, you may evaluate how the addition of Annovis Bio to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Annovis Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Annovis Bio. If investors know Annovis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Annovis Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Annovis Bio is measured differently than its book value, which is the value of Annovis that is recorded on the company's balance sheet. Investors also form their own opinion of Annovis Bio's value that differs from its market value or its book value, called intrinsic value, which is Annovis Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Annovis Bio's market value can be influenced by many factors that don't directly affect Annovis Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Annovis Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Annovis Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Annovis Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.